Peter Ordentlich - 31 Jan 2023 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Scientific Officer
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Issuer symbol
SNDX
Transactions as of
31 Jan 2023
Net transactions value
+$2,568,734
Form type
4
Filing time
03 Feb 2023, 15:59:20 UTC
Previous filing
02 Dec 2022
Next filing
17 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Other $1,195 +69 $17.32 69 31 Jan 2023 Direct F1
transaction SNDX Common Stock Sale $1,962 -69 -100% $28.43 0 01 Feb 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Award $2,569,500 +90,000 $28.55 90,000 02 Feb 2023 Common Stock 90,000 $28.55 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 69 shares by the Reporting Person on 01/31/2023 pursuant to the Issuer's Employee Stock Purchase Plan.
F2 1/48th of the shares subject to the option shall vest monthly over a four-year period.